NurExone Biologic Inc.
NRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 763.00K | 1.13M | 1.08M | 852.00K | 782.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.47M | 1.82M | 1.70M | 1.48M | 1.29M |
| Operating Income | -1.47M | -1.82M | -1.70M | -1.48M | -1.29M |
| Income Before Tax | -1.47M | -1.85M | -1.68M | -1.55M | -1.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.47M | -1.85M | -1.68M | -1.55M | -1.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.47M | -1.85M | -1.68M | -1.55M | -1.25M |
| EBIT | -1.47M | -1.82M | -1.70M | -1.48M | -1.29M |
| EBITDA | -1.42M | -1.78M | -1.66M | -1.47M | -1.27M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 77.59M | 76.03M | 73.61M | 71.08M | 63.53M |
| Average Diluted Shares Outstanding | 77.59M | 76.03M | 73.61M | 71.08M | 63.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |